Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01996046 · ClinicalTrials.gov registry record
FDG PET/CT in Breast Cancer Bone Mets
A clinical trial of Estrogen Receptor-positive Breast Cancer and Bone Metastases, sponsored by University of Pennsylvania.
- Active
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT01996046: Active study of Estrogen Receptor-positive Breast Cancer and Bone Metastases, sponsored by University of Pennsylvania.
NCT01996046 is a study of Estrogen Receptor-positive Breast Cancer and Bone Metastases that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 75 participants, below the 255-participant average among 16 other Estrogen Receptor-positive Breast Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01996046, a study of Estrogen Receptor-positive Breast Cancer and Bone Metastases, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.
Primary Outcome
Date of clinical progression will be recorded
Conditions Studied
Interventions
- OTHER FDG PET/CT scan
Study Locations (1)
Pennsylvania
- University of Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-09 |
| Est. Completion | 2026-07-31 |
What the registry record for NCT01996046 still lists
NCT01996046 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 255-participant average among 16 other Estrogen Receptor-positive Breast Cancer trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Estrogen Receptor-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which FDG PET/CT scan is the first listed.
NCT01996046 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01996046 about?
NCT01996046 is a clinical study titled "FDG PET/CT in Breast Cancer Bone Mets". This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change ...
What is the current status of trial NCT01996046?
This trial is currently active not recruiting. The enrollment target is 75 participants. The study started on 2013-09. Estimated completion is 2026-07-31.
What conditions does trial NCT01996046 study?
This clinical trial studies the following conditions: Estrogen Receptor-positive Breast Cancer, Bone Metastases.
What interventions are being tested in trial NCT01996046?
The interventions under investigation include: FDG PET/CT scan (OTHER).
Who is sponsoring clinical trial NCT01996046?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01996046 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Estrogen Receptor-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01996046's enrollment target sits among peer trials
75 8th of 16 higher than 9 of 16 other Estrogen Receptor-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Estrogen Receptor-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Breast Re-irradiation After Second Ipsilateral Lumpectomy
RECRUITING · NA
-
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia